Engineering and Development

Management and Executive

Legal and Compliance

Customer Service and Support

Chief Financial Officer

Senior Vice President CMC Development

Alnylam Pharmaceuticals Says Amvuttra Reduces Gastrointestinal Events in Study

New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

Alnylam says new data from Helios-B Phase 3 study demonstrate lower rates of gastrointestinal events in ATTR-CM patients treated with Vutrisiran

Alnylam Pharmaceuticals, Inc. Announces New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

Principal Scientist

Alnylam Pharmaceuticals is a leader in RNA interference (RNAi) therapeutics, dedicated to transforming lives through innovative medicines. They are seeking a Principal Scientist to develop and implement bioanalytical methods for proteins, peptides, and RNA, collaborating with cross-functional teams to drive insights into RNAi therapeutic development.

Senior Associate Scientist

Senior Scientist

Senior scientist 1

Principal Associate Scientist

Sign up with Google

Sign in with Google